Kyung Kook Lee – Chairman, KMDIA, South Korea
Kyung Kook Lee, chairman of KMDIA, explains the association’s role in working with the medical devices industry to boost both the local market and to raise Korea’s profile as a…
Korean Pharmaceutical Association (KPA) is a non-profit organization established as Korea Pharmacists Association in 1928. Approximately 60,000 members of KPA have contributed to public health through ‘good quality of medicine and right medication’. With our belief and willingness to improve public health, members of KPA are committed to build a welfare country.
KPA has 16 regional divisions (5 special divisions abroad), 227 branches, General Assembly of Delegates as a legislative body, and 16 standing committees as an executive organization.
KPA has made efforts that pharmacies as the closest health care provider offer good quality of public health care service. KPA has tried to keep the policy of separation of dispensary from medical practice, offer on-going education to pharmacists, renovate and develop pharmacology, improve national health insurance, establish fair trade of medical supplies, promote an information-oriented pharmacology, and build a computerized pharmacy.
In addition, KPA supports various social programs and makes efforts to build social safety networks such as smoking cessation campaign, child protection program, 1388 youth protection campaign, and more.
KPA will try to develop public health service system combining public interests with pharmacists’ right and do the best effort to complete roles of pharmacists under the slogan of ‘pharmacists with pride. KPA in company with public’.
Contact details
Address: 1493-3 Seocho-3 Dong, Seocho-gu, Seoul 137-869 KOREA
Tel: +82 02 581 1201
www.kpanet.or.kr
Kyung Kook Lee, chairman of KMDIA, explains the association’s role in working with the medical devices industry to boost both the local market and to raise Korea’s profile as a…
Jung Hyun Yun lifts the lid on Biosolution’s new stem cell technology that could revolutionize the treatment of cartilage-related ailments, such as osteoarthritis. He also discusses the plans for global…
Antimicrobial resistance (AMR) is a global health concern that we are increasingly understanding the consequences of and pulling together to try and keep under control. Korea is one of the…
Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market,…
The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced…
Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for…
Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical research environment over the past four…
Yong-Ik Kim, president of Korea’s National Health Insurance Service (NHIS), provides an insight into the implementation of the upcoming MoonCare reforms, the government’s strategy to ensure the expansion of coverage…
Kyungjin Peter Kim, CEO of ST Pharm, provides an insight into his expansion of the company’s operations from simply a CMO into a CDMO and new drug development. He also…
Sean Kim, senior director at the Korea Research-Based Pharma Industry Association (KRPIA) gives his assessment of the role of MNCs within the pharma industry in South Korea. At the…
Roger Zbinden, head of the Swiss Business Hub Korea, explains their efforts to raise the profile of the South Korean market for Swiss business. Dr Zbinden also provides his insights…
National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of…
See our Cookie Privacy Policy Here
